Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
DermTech Inc is a diagnostics & research business based in the US. DermTech shares (DMTK) are listed on the NASDAQ and all prices are listed in US Dollars. DermTech employs 114 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $12.37 |
|---|---|
| 52-week range | $11.01 - $84.49 |
| 50-day moving average | $17.90 |
| 200-day moving average | $31.62 |
| Wall St. target price | $49.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.34 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.37 from 2022-01-24
| 1 week (2022-01-18) | -6.22% |
|---|---|
| 1 month (2021-12-23) | -31.12% |
| 3 months (2021-10-25) | -59.39% |
| 6 months (2021-07-23) | -65.16% |
| 1 year (2021-01-25) | -72.80% |
|---|---|
| 2 years (2020-01-24) | -6.64% |
| 3 years (2019-01-25) | 20.33% |
| 5 years (2017-01-21) | N/A |
| Revenue TTM | $10.8 million |
|---|---|
| Gross profit TTM | $-96,000 |
| Return on assets TTM | -22.75% |
| Return on equity TTM | -40.61% |
| Profit margin | 0% |
| Book value | $8.48 |
| Market capitalisation | $367.6 million |
TTM: trailing 12 months
We're not expecting DermTech to pay a dividend over the next 12 months.
DermTech's shares were split on a 1:2 basis on 29 August 2019. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DermTech shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for DermTech shares which in turn could have impacted DermTech's share price.
Over the last 12 months, DermTech's shares have ranged in value from as little as $11.01 up to $84.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DermTech's is 0.711. This would suggest that DermTech's shares are less volatile than average (for this exchange).
DermTech, Inc. , a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.